223 related articles for article (PubMed ID: 35507508)
41. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
Zhu FC; Li YH; Guan XH; Hou LH; Wang WJ; Li JX; Wu SP; Wang BS; Wang Z; Wang L; Jia SY; Jiang HD; Wang L; Jiang T; Hu Y; Gou JB; Xu SB; Xu JJ; Wang XW; Wang W; Chen W
Lancet; 2020 Jun; 395(10240):1845-1854. PubMed ID: 32450106
[TBL] [Abstract][Full Text] [Related]
42. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
[TBL] [Abstract][Full Text] [Related]
43. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.
Sadoff J; Gray G; Vandebosch A; Cárdenas V; Shukarev G; Grinsztejn B; Goepfert PA; Truyers C; Van Dromme I; Spiessens B; Vingerhoets J; Custers J; Scheper G; Robb ML; Treanor J; Ryser MF; Barouch DH; Swann E; Marovich MA; Neuzil KM; Corey L; Stoddard J; Hardt K; Ruiz-Guiñazú J; Le Gars M; Schuitemaker H; Van Hoof J; Struyf F; Douoguih M;
N Engl J Med; 2022 Mar; 386(9):847-860. PubMed ID: 35139271
[TBL] [Abstract][Full Text] [Related]
44. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI
Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141
[TBL] [Abstract][Full Text] [Related]
45. Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial.
Nguyen TP; Do Q; Phan LT; Dinh DV; Khong H; Hoang LV; Nguyen TV; Pham HN; Chu MV; Nguyen TT; Pham QD; Le TM; Trang TNT; Dinh TT; Vo TV; Vu TT; Nguyen QBP; Phan VT; Nguyen LV; Nguyen GT; Tran PM; Nghiem TD; Tran TV; Nguyen TG; Tran TQ; Nguyen LT; Do AT; Nguyen DD; Ho SA; Nguyen VT; Pham DT; Tran HB; Vu ST; Hoang SX; Do TM; Nguyen XT; Le GQ; Tran T; Cao TM; Dao HM; Nguyen TTT; Doan UY; Le VTT; Tran LP; Nguyen NM; Nguyen NT; Pham HTT; Nguyen QH; Nguyen HT; Nguyen HLK; Tran VT; Tran MTN; Nguyen TTT; Ha PT; Huynh HT; Nguyen KD; Thuan UT; Doan CC; Do SM
Lancet Reg Health West Pac; 2022 Jul; 24():100474. PubMed ID: 35602004
[TBL] [Abstract][Full Text] [Related]
46. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
Stephenson KE; Wegmann F; Tomaka F; Walsh SR; Tan CS; Lavreys L; Ansel JL; Kanjilal DG; Jaegle K; Nkolola JP; Peter L; Fogel R; Bradshaw C; Tyler A; Makoni T; Howe L; Quijada D; Chandrashekar A; Bondzie EA; Borducchi EN; Yanosick KE; Hendriks J; Nijs S; Truyers C; Tolboom J; Zahn RC; Seaman MS; Alter G; Stieh DJ; Pau MG; Schuitemaker H; Barouch DH
Lancet HIV; 2020 Jun; 7(6):e410-e421. PubMed ID: 32078815
[TBL] [Abstract][Full Text] [Related]
47. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
48. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
Levin MJ; Ustianowski A; De Wit S; Launay O; Avila M; Templeton A; Yuan Y; Seegobin S; Ellery A; Levinson DJ; Ambery P; Arends RH; Beavon R; Dey K; Garbes P; Kelly EJ; Koh GCKW; Near KA; Padilla KW; Psachoulia K; Sharbaugh A; Streicher K; Pangalos MN; Esser MT;
N Engl J Med; 2022 Jun; 386(23):2188-2200. PubMed ID: 35443106
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study.
Dayan GH; Rouphael N; Walsh SR; Chen A; Grunenberg N; Allen M; Antony J; Bhate AS; Beresnev T; Bonaparte MI; Celle M; Ceregido MA; Corey L; Fu B; Grillet MH; Keshtkar-Jahromi M; Juraska M; Kee JJ; Kaali S; Koutsoukos M; Masotti R; Michael NL; Neuzil KM; Reynales H; Robb ML; Uchiyama A; Sawe F; Schuerman L; Shrestha R; Tong T; Treanor J; Diazgranados CA; Chicz RM; Gurunathan S; Savarino S; Sridhar S;
EClinicalMedicine; 2023 Oct; 64():102168. PubMed ID: 37936652
[TBL] [Abstract][Full Text] [Related]
50. Six-month safety follow-up of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in adults: A phase 2/3, double-blind, randomized study.
Hosain R; Aquino P; Baccarini C; Smolenov I; Li P; Qin H; Verhoeven C; Hu B; Huang Y; Rubio P;
Vaccine; 2023 Mar; 41(13):2253-2260. PubMed ID: 36868877
[TBL] [Abstract][Full Text] [Related]
51. Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers.
Pittet LF; Messina NL; Orsini F; Moore CL; Abruzzo V; Barry S; Bonnici R; Bonten M; Campbell J; Croda J; Dalcolmo M; Gardiner K; Gell G; Germano S; Gomes-Silva A; Goodall C; Gwee A; Jamieson T; Jardim B; Kollmann TR; Lacerda MVG; Lee KJ; Lucas M; Lynn DJ; Manning L; Marshall HS; McDonald E; Munns CF; Nicholson S; O'Connell A; de Oliveira RD; Perlen S; Perrett KP; Prat-Aymerich C; Richmond PC; Rodriguez-Baño J; Dos Santos G; da Silva PV; Teo JW; Villanueva P; Warris A; Wood NJ; Davidson A; Curtis N;
N Engl J Med; 2023 Apr; 388(17):1582-1596. PubMed ID: 37099341
[TBL] [Abstract][Full Text] [Related]
52. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults.
Anderson EJ; Rouphael NG; Widge AT; Jackson LA; Roberts PC; Makhene M; Chappell JD; Denison MR; Stevens LJ; Pruijssers AJ; McDermott AB; Flach B; Lin BC; Doria-Rose NA; O'Dell S; Schmidt SD; Corbett KS; Swanson PA; Padilla M; Neuzil KM; Bennett H; Leav B; Makowski M; Albert J; Cross K; Edara VV; Floyd K; Suthar MS; Martinez DR; Baric R; Buchanan W; Luke CJ; Phadke VK; Rostad CA; Ledgerwood JE; Graham BS; Beigel JH;
N Engl J Med; 2020 Dec; 383(25):2427-2438. PubMed ID: 32991794
[TBL] [Abstract][Full Text] [Related]
53. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
[TBL] [Abstract][Full Text] [Related]
54. Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine.
Petrovsky N
Hum Vaccin Immunother; 2024 Dec; 20(1):2363016. PubMed ID: 38839044
[TBL] [Abstract][Full Text] [Related]
55. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.
Jackson LA; Campbell JD; Frey SE; Edwards KM; Keitel WA; Kotloff KL; Berry AA; Graham I; Atmar RL; Creech CB; Thomsen IP; Patel SM; Gutierrez AF; Anderson EL; El Sahly HM; Hill H; Noah DL; Bellamy AR
JAMA; 2015 Jul; 314(3):237-46. PubMed ID: 26197184
[TBL] [Abstract][Full Text] [Related]
56. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.
Yang WH; Dionne M; Kyle M; Aggarwal N; Li P; Madariaga M; Godeaux O; Vaughn DW
Vaccine; 2013 Sep; 31(40):4389-97. PubMed ID: 23856331
[TBL] [Abstract][Full Text] [Related]
57. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA;
Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of adjuvant-associated COVID-19 vaccines against SARS-CoV-2 variants of concern in randomized controlled trials: A systematic review and meta-analysis.
Cheng MQ; Weng ZY; Li R; Song G
Medicine (Baltimore); 2024 Feb; 103(7):e35201. PubMed ID: 38363919
[TBL] [Abstract][Full Text] [Related]
59. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.
Li J; Hui A; Zhang X; Yang Y; Tang R; Ye H; Ji R; Lin M; Zhu Z; Türeci Ö; Lagkadinou E; Jia S; Pan H; Peng F; Ma Z; Wu Z; Guo X; Shi Y; Muik A; Şahin U; Zhu L; Zhu F
Nat Med; 2021 Jun; 27(6):1062-1070. PubMed ID: 33888900
[TBL] [Abstract][Full Text] [Related]
60. Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults.
Ahn JY; Lee J; Suh YS; Song YG; Choi YJ; Lee KH; Seo SH; Song M; Oh JW; Kim M; Seo HY; Kwak JE; Youn JW; Woo JW; Shin EC; Sung YC; Park SH; Choi JY
Lancet Microbe; 2022 Mar; 3(3):e173-e183. PubMed ID: 35156068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
